Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1

Dysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut mi...

Full description

Bibliographic Details
Main Authors: Catharina Missailidis, Nikolaj Sørensen, Senait Ashenafi, Wondwossen Amogne, Endale Kassa, Amsalu Bekele, Meron Getachew, Nebiat Gebreselassie, Abraham Aseffa, Getachew Aderaye, Jan Andersson, Susanna Brighenti, Peter Bergman
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/11/7/1675
id doaj-f85d4b36b8e640b0b5c716675df41400
record_format Article
spelling doaj-f85d4b36b8e640b0b5c716675df414002020-11-25T01:26:23ZengMDPI AGNutrients2072-66432019-07-01117167510.3390/nu11071675nu11071675Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1Catharina Missailidis0Nikolaj Sørensen1Senait Ashenafi2Wondwossen Amogne3Endale Kassa4Amsalu Bekele5Meron Getachew6Nebiat Gebreselassie7Abraham Aseffa8Getachew Aderaye9Jan Andersson10Susanna Brighenti11Peter Bergman12Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, SwedenClinical Microbiomics, 2200 Copenhagen, DenmarkCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaArmauer Hansen Research Institute (AHRI), 1005 Addis Ababa, EthiopiaArmauer Hansen Research Institute (AHRI), 1005 Addis Ababa, EthiopiaDepartment of Internal Medicine, Faculty of Medicine, Black Lion University Hospital and Addis Ababa University, 1176 Addis Ababa, EthiopiaCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenCenter for Infectious Medicine (CIM), F59, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, 14152 Stockholm, SwedenDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152 Stockholm, SwedenDysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut microbiota. Treatment-na&#239;ve HIV-1-infected individuals (<i>n</i> = 167) were included from a double-blind, randomized, and placebo-controlled trial of daily 5000 IU vitamin D and 500 mg phenylbutyrate for 16 weeks (Clinicaltrials.gov NCT01702974). Baseline and per-protocol plasma samples at week 16 were analysed for soluble CD14, the antimicrobial peptide LL-37, kynurenine/tryptophan-ratio, TMAO, choline, and betaine. Assessment of the gut microbiota involved 16S rRNA gene sequencing of colonic biopsies. Vitamin D + phenylbutyrate treatment significantly increased 25-hydroxyvitamin D levels (<i>p</i> &lt; 0.001) but had no effects on sCD14, the kynurenine/tryptophan-ratio, TMAO, or choline levels. Subgroup-analyses of vitamin D insufficient subjects demonstrated a significant increase of LL-37 in the treatment group (<i>p</i> = 0.02), whereas treatment failed to significantly impact LL-37-levels in multiple regression analysis. Further, no effects on the microbiota was found in number of operational taxonomic units (<i>p</i> = 0.71), Shannon microbial diversity index (<i>p</i> = 0.82), or in principal component analyses (<i>p</i> = 0.83). Nutritional supplementation with vitamin D + phenylbutyrate did not modulate gut-derived inflammatory markers or microbial composition in treatment-na&#239;ve HIV-1 individuals with active viral replication.https://www.mdpi.com/2072-6643/11/7/1675HIV-1vitamin Dphenylbutyrateclinical trialTMAOmicrobiotaLL-37kynurenine/tryptophan ratio
collection DOAJ
language English
format Article
sources DOAJ
author Catharina Missailidis
Nikolaj Sørensen
Senait Ashenafi
Wondwossen Amogne
Endale Kassa
Amsalu Bekele
Meron Getachew
Nebiat Gebreselassie
Abraham Aseffa
Getachew Aderaye
Jan Andersson
Susanna Brighenti
Peter Bergman
spellingShingle Catharina Missailidis
Nikolaj Sørensen
Senait Ashenafi
Wondwossen Amogne
Endale Kassa
Amsalu Bekele
Meron Getachew
Nebiat Gebreselassie
Abraham Aseffa
Getachew Aderaye
Jan Andersson
Susanna Brighenti
Peter Bergman
Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
Nutrients
HIV-1
vitamin D
phenylbutyrate
clinical trial
TMAO
microbiota
LL-37
kynurenine/tryptophan ratio
author_facet Catharina Missailidis
Nikolaj Sørensen
Senait Ashenafi
Wondwossen Amogne
Endale Kassa
Amsalu Bekele
Meron Getachew
Nebiat Gebreselassie
Abraham Aseffa
Getachew Aderaye
Jan Andersson
Susanna Brighenti
Peter Bergman
author_sort Catharina Missailidis
title Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
title_short Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
title_full Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
title_fullStr Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
title_full_unstemmed Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1
title_sort vitamin d and phenylbutyrate supplementation does not modulate gut derived immune activation in hiv-1
publisher MDPI AG
series Nutrients
issn 2072-6643
publishDate 2019-07-01
description Dysbiosis and a dysregulated gut immune barrier function contributes to chronic immune activation in HIV-1 infection. We investigated if nutritional supplementation with vitamin D and phenylbutyrate could improve gut-derived inflammation, selected microbial metabolites, and composition of the gut microbiota. Treatment-na&#239;ve HIV-1-infected individuals (<i>n</i> = 167) were included from a double-blind, randomized, and placebo-controlled trial of daily 5000 IU vitamin D and 500 mg phenylbutyrate for 16 weeks (Clinicaltrials.gov NCT01702974). Baseline and per-protocol plasma samples at week 16 were analysed for soluble CD14, the antimicrobial peptide LL-37, kynurenine/tryptophan-ratio, TMAO, choline, and betaine. Assessment of the gut microbiota involved 16S rRNA gene sequencing of colonic biopsies. Vitamin D + phenylbutyrate treatment significantly increased 25-hydroxyvitamin D levels (<i>p</i> &lt; 0.001) but had no effects on sCD14, the kynurenine/tryptophan-ratio, TMAO, or choline levels. Subgroup-analyses of vitamin D insufficient subjects demonstrated a significant increase of LL-37 in the treatment group (<i>p</i> = 0.02), whereas treatment failed to significantly impact LL-37-levels in multiple regression analysis. Further, no effects on the microbiota was found in number of operational taxonomic units (<i>p</i> = 0.71), Shannon microbial diversity index (<i>p</i> = 0.82), or in principal component analyses (<i>p</i> = 0.83). Nutritional supplementation with vitamin D + phenylbutyrate did not modulate gut-derived inflammatory markers or microbial composition in treatment-na&#239;ve HIV-1 individuals with active viral replication.
topic HIV-1
vitamin D
phenylbutyrate
clinical trial
TMAO
microbiota
LL-37
kynurenine/tryptophan ratio
url https://www.mdpi.com/2072-6643/11/7/1675
work_keys_str_mv AT catharinamissailidis vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT nikolajsørensen vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT senaitashenafi vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT wondwossenamogne vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT endalekassa vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT amsalubekele vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT merongetachew vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT nebiatgebreselassie vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT abrahamaseffa vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT getachewaderaye vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT janandersson vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT susannabrighenti vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
AT peterbergman vitamindandphenylbutyratesupplementationdoesnotmodulategutderivedimmuneactivationinhiv1
_version_ 1725109220502667264